37 results about "Transcription regulator" patented technology

The invention relates to a culture medium for preparing neural stem cells and an application of the culture medium. The culture medium for preparing the neural stem cells comprises a culture medium suitable for the growth of stem cells, and a cell signal pathway inhibitor which is selected from at least one of the following agents: a GSK (Glaxo Smith Klein) inhibitor, an MEK (Methyl Ethyl Ketone) inhibitor, a TGF (Transforming Growth Factor)-beta inhibitor, a ROCK inhibitor and a BMP inhibitor. The somatic cells are cultured by using the culture medium, especially the somatic cells for expressing the transcription regulator are cultured, so as to effectively transdifferentiate the somatic cells into neutral stem cells and the transdifferentiation time is greatly shortened.

The invention encompasses a novel method of treating inflammatory disease, such as rheumatoid arthritis, and novel methods of identifying and screening for drugs useful in the treatment of inflammatory diseases and their clinical symptoms. The inventors have made the discovery that the activity of HIF-1α, a transcription regulator known to have an effect on some cancers, has a significant impact on the pathophysiology of rheumatoid arthritis. The symptoms of an inflammatory disease, such as rheumatoid arthritis, may be alleviated by administering a compound that inhibits the activity of HIF-1α.

This invention is intended to search for a transcription regulator having a novel function of improving the amount of substances produced per individual plant and to enhance such properties in a plant. A chimeric protein resulting from the fusion of a transcription factor belonging a transcription factor family that includes a transcription factor comprising the amino acid sequence as shown in SEQ ID NO: 4 with the repressor domain is expressed in a plant.

The present application discloses a method for making and selecting a transcription enhancing combined promoter cassette, which includes constructing a library of randomly combined transcription regulatory elements, which comprise double stranded DNA sequence elements that are recognized by transcription regulators; inserting the combined transcription regulatory elements upstream of a minimum promoter followed by a reporter gene in a vector; inserting the vector into a host cell; and then screening for the cells showing enhanced expression of the reporter gene, and identifying the combined promoter cassette in the cell.

Dysfunctional or exhausted T cells arise in chronic diseases including chronic viral infections and cancer, and express high levels of co-inhibitory receptors. Therapeutic blockade of these receptors has clinical efficacy in the treatment of cancer. While co-inhibitory receptors are co-expressed, the triggers that induce them and the transcriptional regulators that drive their co-expression have not been identified. The immunoregulatory cytokine IL-27 induces a gene module in T cells that includes several known co-inhibitory receptors (Tim-3, Lag-3, and TIGIT). The present invention provides a novel immunoregulatory network as well as novel cell surface molecules that have an inhibitory function in the tumor microenvironment. The present invention further provides the novel discovery that the transcription factors Prdm1 and c-Maf cooperatively regulate the expression of the co-inhibitory receptor module. This critical molecular circuit underlies the co-expression of co-inhibitory receptors in dysfunctional T cells and identifies novel regulators of T cell dysfunction.

The present invention provides a method for the fermentative production of compactin, lovastatin, pravastatin or simvastatin comprising culturing a host, preferably a filamentous fungus, comprising the polynucleotide of the lovE transcription regulator gene from Aspergillus terreus. Furthermore, the invention provides a host for the production of above mentioned statines comprising the polynucleotide of the lovE transcription regulator gene from Aspergillus terreus.

The present invention provides an isolated polynucleotide comprising the kstD promoter from Rhodococcus erythrypolis. The polynucleotide can very advantageously be used as a controllable transcription activator. Said controlling function can be provided by providing said isolated polynucleotide with a nucleotide sequence encoding a transcription regulator of said promoter. In the present invention, such a transcription regulator may be externally induced, such as by introduction of steroidal compounds. In an alternative embodiment of the present invention the isolated polynucleotide may comprise the kstR gene or a homologue or a functional part thereof as the transcription regulator of the kstD promoter.

The invention discloses a bacteriophage trp574 gene and application thereof. A nucleotide sequence of the bacteriophage trp574 gene is as shown by SEQ ID NO:1, and a coded amino acid sequence of the bacteriophage trp574 gene is as shown by SEQ ID NO:2. The invention discloses a transcriptional regulation factor trp574 gene belonging to the XRE family for the first time, and researches of the invention shows that a ralstonia solanacearum strain into which the trp574 gene is transformed almost loses pathogenicity, and the trp574 gene has the comprehensive effects of remarkably interfering the growth, metabolism, pathogenicity and the like of ralstonia solanacearum, can be used for preparing ralstonia solanacearum strains without pathogenicity, and has a great application prospect in preventing and treating bacterial wilt.

The present invention relates to a promoter system inducing expression of 3-hydroxypropionic acid (3-HP) and a method of biologically producing 3-HP using the same. To improve production of 3-HP in a biological manner, continuous synthesis of new enzymes having enzyme activity is necessary. As a result of screening 3-HP reactive transcription regulators and 3-HP reactive promoters from several microorganisms including Pseudomonas denitrificans, it was confirmed that the transcriptions regulations and promoters are composed of LysR proteins and particular gene nucleotide sequences binding to the LysR proteins. Therefore, the 3-HP inducible system is expected to be effectively used to regulate 3-HP metabolic pathways.

The present application discloses a method for making and selecting a transcription enhancing combined promoter cassette, which includes constructing a library of randomly combined transcription regulatory elements, which comprise double stranded DNA sequence elements that are recognized by transcription regulators; inserting the combined transcription regulatory elements upstream of a minimum promoter followed by a reporter gene in a vector; inserting the vector into a host cell; and then screening for the cells showing enhanced expression of the reporter gene, and identifying the combined promoter cassette in the cell.

The invention relates to methods of producing a desired phenotype in a plant by manipulation of gene expression within the plant. The method relates to means to increase expression level of a bHLH subgroup Ib gene expression or activity, wherein a desired phenotype such as increased heat tolerance relative to a wild type control plant following heat stress results in reduced flower abortion and increased yield. Included are plants produced by said methods. The invention also relates to nucleic acid sequences and constructs useful such methods and methods of generating and isolating plants having increased expression of a bHLH subgroup Ib expression or activity.

The present invention provides a novel fructose responsive transcription control cis-element and a transcriptional regulatory factor that interacts therewith, a non-human animal having them transferred or inactivated, a diagnostic method for genetic susceptibility to a metabolic disorder using them, and a screening method for a prophylactic or therapeutic drug for a metabolic disorder using them.

The present invention provides a kit comprising a cell transfected with hepatic transcription regulators, and a culture medium that support growth of the cell. The present invention further provides a method for determining drug metabolism and predicting drug toxicity, comprising transfecting a cell with hepatic transcription regulators, and culturing the cell on a medium.

Provided is the use of an aromatic ring drug in inhibiting a key transcription factor of malignant melanoma. In particular, provided is the use of a compound as represented by formula A, or an optical isomer thereof or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition or preparation. The pharmaceutical composition or preparation is used for: (a) inhibiting a key transcriptional regulatory factor of malignant melanoma, namely MITF (Microphthalmia-associated Transcription Factor); (b) treating MITF-related diseases such as melanoma, pancreatic cancer, skin hypersensitivity and asthma; and (c) regulating physiological activities in which MITF is involved, such as skin whitening. In the formula, each group is as defined in the description.

The invention belongs to the biomedical field and relates to the application of p53 in preparing for a drug preparation for remedying the tumor. A p53 gene coding product is a transcription regulator which can induce the apoptosis or the block of the cell cycle by regulating lower target gene. An over-expression of the p53 can very effectively induce the apoptosis of tumor cells. Attenuated salmonella typhimurium can be used as a carrier to introduce the p53 to express inside the tumor cells and kill the tumor cells. The development of a novel treatment drug which considers the salmonella with the p53 as orally taken gene not only solves the problem of non-injection path of a protein polypeptide drug but also more importantly provides the tumor treatment with a safe, effective, peculiar and economical method.

The invention discloses a transcriptional regulatory factor PfaR for promoting synthesis of shewanella eicosapentaenoic acid (EPA, C20: 5 omega 3) and application of the transcriptional regulatory factor PfaR, the nucleotide sequence of the transcriptional regulatory factor PfaR is as shown in SEQ ID NO.1, gene knockout and real-time fluorescent quantitative PCR (RT-qPCR) prove that the PfaR serves as a positive regulatory factor to participate in regulation and control of shewanella eicosapentaenoic acid synthesis at low temperature, and the PfaR can be used for promoting synthesis of shewanella eicosapentaenoic acid (EPA, C20: 5 omega 3). Meanwhile, it is proved that the EPA content of shewanella at low temperature can be increased through overexpression of the transcriptional regulatory factor PfaR. Therefore, the transcriptional regulatory factor PfaR promotes the shewanella to synthesize the EPA at low temperature, and plays an important role in related genetic improvement for improving the synthesis of the shewanella EPA.

The invention discloses a gene sequence with a molecular switch, a plasmid and an immune cell, and belongs to the technical field of molecular biology. The gene sequence comprises an excitation component, a connection region and a response component, wherein the excitation component comprises a target binding region and a transcription regulation region; the response component comprises an expression region and a promoter region matched with the transcription regulation region; the target binding region of the excitation component is used for expressing a target binding receptor; the transcription regulation region is used for expressing a transcription regulation factor; after the target binding receptor is used for being bound with a target, the transcription regulation factor is separated from the target binding receptor, is bound to the promoter region, and activates a promoter to start expression of the gene sequence in the expression region; and the connection region connects the excitation component and the response component in the same gene sequence. The preparation flow is simplified, the transfection efficiency is improved, and industrial preparation of virus particles and CAR cells is facilitated.

Provided is the use of an aromatic ring drug in inhibiting a key transcription factor of malignant melanoma. In particular, provided is the use of a compound as represented by formula A, or an optical isomer thereof or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition or preparation. The pharmaceutical composition or preparation is used for: (a) inhibiting a key transcriptional regulatory factor of malignant melanoma, namely MITF (Microphthalmia-associated Transcription Factor); (b) treating MITF-related diseases such as melanoma, pancreatic cancer, skin hypersensitivity and asthma; and (c) regulating physiological activities in which MITF is involved, such as skin whitening. In the formula, each group is as defined in the description.

The invention discloses a preparation method of dendrobium alkaloid, a medicine containing the dendrobium alkaloid and application of the dendrobium alkaloid in preparation of the medicine for treating and inhibiting cholestasis. The dendrobium alkaloid treatment has the obvious effect of protecting DDC from causing intrahepatic cholestasis liver injury, bile acid efflux can be improved by up-regulating Fxr expression, an upstream signal channel of a transcriptional regulation factor Nrf2 is enhanced to promote Nrf2 expression, and the expression quantity of a downstream target gene is further increased, so that the anti-oxidative stress effect of a body is enhanced.

The present application discloses a method for making and selecting a transcription enhancing combined promoter cassette, which includes constructing a library of randomly combined transcription regulatory elements, which comprise double stranded DNA sequence elements that are recognized by transcription regulators; inserting the combined transcription regulatory elements upstream of a minimum promoter followed by a reporter gene in a vector; inserting the vector into a host cell; and then screening for the cells showing enhanced expression of the reporter gene, and identifying the combined promoter cassette in the cell.

The invention discloses a diagnostic kit for detecting recurrent spontaneous abortion based on abnormal expression of a trophoblast NLRC5 gene. Comprising an NLRC5 gene expression detection reagent and an NLRC5 protein expression detection reagent. The NLRC5 gene expression detection reagent is used for detecting the expression quantity of NLRC5 gene mRNA of trophoblast cells. The NLRC5 protein expression detection reagent is used for detecting the expression of the protein coded by the NLRC5 of the trophoblast. As one of NOD-like protein family members, NLRC5 is a key transcriptional regulatory factor of MHC-I type molecular gene expression. In combination with a part of results of the embodiment of the invention, the abnormal expression of the NLRC5 gene can be clearly detected in the RSA trophoblast, and the abnormal expression of the NLRC5 gene does not appear in normal tissues, so that the abnormal expression of the NLRC5 gene can be used as a target for detecting the recurrent spontaneous abortion. In addition, the invention also discloses application of the NLRC5 gene in preparation of diagnostic drugs and diagnostic reagents for recurrent spontaneous abortion.

The invention belongs to the biomedical field and relates to the application of KILLER polypeptide in the preparation of a drug for remedying the tumor. A KILLER gene encoding production is a TRAIL accepter of cell surface as well as a lower target gene of a transcription regulator p53. An over-expression of the KILLER can very effectively induce the apoptosis of tumor cells. Attenuated salmonella typhimurium can be used as a carrier to introduce the KILLER to express inside the tumor cells and kill the tumor cells. The development of a novel treatment drug which considers the salmonella with the KILLER as orally taken gene not only solves the problem of non-injection path of a protein polypeptide drug but also more importantly provides the tumor treatment with a safe, effective, peculiar and economical method.